Coral Drugs

Executive Summary

Coral Drugs is a well-established Indian contract manufacturing organization (CMO) specializing in high-quality active pharmaceutical ingredients (APIs) for steroids, hormones, antihistamines, and antineoplastics. Founded in 1996, the company operates vertically integrated, cGMP-certified facilities in New Delhi, employing 200-500 people. Its advanced particle engineering capabilities and end-to-end API production allow it to serve global pharmaceutical customers reliably, particularly in complex therapeutic categories. Coral Drugs has built a reputation for regulatory compliance and consistent quality, enabling long-term partnerships with innovator and generic drug companies worldwide. The company’s conviction score of 65 reflects its stable position in the API contract manufacturing market, supported by growing demand for specialty APIs and cost-efficient production in India. While Coral Drugs is not a drug developer with a pipeline, its growth hinges on expanding its manufacturing capacity, entering new therapeutic areas, and securing new contracts. Key upcoming catalysts include the commissioning of a new production line for high-potency APIs and the potential signing of a multi-year supply agreement with a top-10 pharma company. These events could drive revenue growth and margin expansion over the next 12-18 months.

Upcoming Catalysts (preview)

• Q3 2026Commissioning of new high-potency API production line80% success
• Q4 2026Multi-year supply agreement with a top-10 pharma company50% success